Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics
Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range
Rijswijk, The Netherlands, May 19, 2022 (GLOBE NEWSWIRE) --
- Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistance
- The company is the first to publicly announce that Its entire supply chain of oral antibiotics – including its own and supplier manufacturing sites - is fully compliant with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance
- This achievement demonstrates Centrient Pharmaceuticals’ commitment and leadership in the responsible production of antibiotics.
Centrient Pharmaceuticals announces 100% compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral antibiotics product range. This standard covers both Centrient’s sites and its suppliers’ sites. This achievement positions the company as a frontrunner in the industry with the delivery of responsibly-produced antibiotics, which minimize the possible contribution to antimicrobial resistance.
The PNEC discharge target is the concentration of an antibiotic in water at which there is unlikely to be a risk of adverse environmental effects or of antimicrobial resistance (AMR) developing. These scientific, risk-based targets were developed by the AMR Industry Alliance and cover around 120 active pharmaceutical ingredients (APIs) used in antibiotic manufacturing. Each individual antibiotic has a corresponding PNEC value, published in the AMR Industry Alliance table of Recommended PNECs for Risk Assessments (updated periodically).
High concentrations of antibiotic residues in factory wastewater can create hotspots of resistant bacteria which may lead to AMR. While manufacturing is just one of the contributors to the emergence of AMR in the environment, its impact cannot be overlooked. AMR is a major threat to global public health as well as to the healthcare industry. Many standard medical procedures such as organ transplants, chemotherapy, and surgeries such as caesarean sections become much more dangerous without effective antibiotics to prevent and treat infections. Antibiotics are the cornerstone of our modern healthcare system, and complying with PNEC standards enables manufacturers to ensure supply of these critically important medicines does not contribute to the risk of AMR.
The PNEC values are increasingly being recognized as the standard for antibiotic discharge concentrations in water and are expanding beyond Alliance companies and their supply chains. For example, tenders in the UK and Germany (health insurer AOK) include a specific reference to the PNEC discharge targets. Also, companies assessed externally by organizations such as the Access to Medicine Foundation will have public exposure for their performance on PNECs.
As a strong advocate for sustainable manufacturing, Centrient Pharmaceuticals became a founding board member of the AMR Industry Alliance in 2017, working with partners to raise awareness and deliver solutions to the AMR issue. Since then, the company’s own journey to reaching full compliance has included establishing state-of-the-art wastewater treatment facilities at all their sites worldwide and developing tests for measuring antibiotic activity in wastewater streams, leading to a fully clean and PNEC-compliant supply chain.
“We are proud to be the first in our industry to publicly announce PNEC compliance for our oral antibiotics product supply chain.
At Centrient Pharmaceuticals, our commitment to Sustainability is in our DNA – we ensure that the way in which we produce pharmaceuticals has the lowest environmental impact and does not contribute to AMR. We are proud of our PureActives® enzymatic low-carbon technology, ISO 14001 certification of all our sites, and Board positions at the Pharmaceutical Supply Chain Initiative and AMR Industry Alliance.
We will continue to work with customers, suppliers, industry and government decision-makers across the value chain to make the supply and buying of antibiotics sustainable to curb AMR.”, says Rex Clements, CEO at Centrient Pharmaceuticals.
Read our whitepaper ‘Manufacturing sustainable antibiotics for the future’ here.
About Centrient Pharmaceuticals
Centrient Pharmaceuticals is the global leader in the production and commercialisation of sustainable antibiotics, next-generation statins, and anti-fungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms.
We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 2,200 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.
Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rijswijk (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm.
For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. E-Mail: email@example.com.
About the AMR Industry Alliance
The AMR Industry Alliance was formed in 2017. With approximately 100 life sciences companies and trade associations, it represents nearly one-third of the volume of sales and the majority of all novel products. Members have committed to report on activities they are undertaking in the areas of research & science, access to antibiotics and appropriate use of these, as well as responsible environmental manufacturing to tackle the rapid spread of antimicrobial resistance. If AMR remains unchecked, the annual death toll could climb from 700,000 each year to 10 million by 2050 and the economic impacts could be on par with those of the 2008 financial crisis. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap for Progress on Combating AMR and measures progress made in the fight against AMR.
This press release may contain forward-looking statements with respect to Centrient Pharmaceuticals’ future financial performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release
REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens
Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release
24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au
Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo
Cool Company Ltd. – Mandatory Notification Of Trade24.6.2022 11:01:19 CEST | Press release
EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 23 June 2022 acquired 7,865 shares in the Company at a price of NOK 90.274882 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,591,218 shares in the Company, equivalent to 38.97% of the Company’s shares. Please see the attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form